Use of cetuximab in a real-life setting in France with respect to KRAS status: Preliminary results of EREBUS cohort study.

@article{Smith2011UseOC,
  title={Use of cetuximab in a real-life setting in France with respect to KRAS status: Preliminary results of EREBUS cohort study.},
  author={Denis Smith and Magali Rouyer and {\'E}ric François and Emmanuel Mitry and Alain Monnereau and Ant{\'o}nio S{\'a} Cunha and Emmanuelle Bignon and Alise Le Monies and Nicholas Moore and Annie Fourrier-R{\'e}glat},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2011},
  volume={29 15_suppl},
  pages={e14094}
}
e14094 Background: Cetuximab demonstrated survival outcome improvement in metastatic colorectal cancer (mCRC). Cetuximab was first launched as a second-line therapy in mCRC. In July 2008, this indication was extended to first-line therapy and restricted to mCRC patients with wild-type (wt) KRAS gene. We present here the preliminary results of the French EREBUS cohort study to describe cetuximab prescription patterns according to KRAS status in a real-life setting. METHODS EREBUS is a cohort… CONTINUE READING